Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study Evaluating the Safety, Tolerance, Immune Response, and Initial Efficacy of Autologous Tumor Infiltrating Lymphocytes (TILs) LM103 Injection in Patients With Advanced Solid Tumors

NCT05971576 is registered in ClinicalTrials.gov with Suzhou BlueHorse Therapeutics Co., Ltd. as lead sponsor.

NCT NCT05971576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05971576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study Evaluating the Safety, Tolerance, Immune Response, and Initial Efficacy of Autologous Tumor Infiltrating Lymphocytes (TILs) LM103 Injection in Patients With Advanced Solid Tumors
Lead sponsor
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2023
Completion date
August 31, 2026
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor